Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 3, 2011, Pages 221-240

  Wildiers, Hans ^a   Reiser, Marcel ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Breast cancer; Chemotherapy; G CSF; Non Hodgkin's lymphoma; Relative dose intensity; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TAMOXIFEN; VINCRISTINE;

AGE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG RESPONSE; EARLY CANCER; FEBRILE NEUTROPENIA; HUMAN; NONHODGKIN LYMPHOMA; OBESITY; PROGNOSIS; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 79952188558     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.02.002     Document Type: Review

References (92)

1. Green J.A., Dawson A.A., Fell L.F., Murray S. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol 1980, 9:511-514.
2. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2:1281-1288.
3. Link B.K., Budd G.T., Scott S., et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 2001, 92:1354-1367.
4. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981, 304:10-15.
5. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995, 332:901-906.
6. Hryniuk W., Levine M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986, 4:1162-1170.
7. Wood W.C., Budman D.R., Korzun A.H., et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994, 330:1253-1259.
8. Howell A., Rubens R.D., Bush H., et al. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Recent Results Cancer Res 1984, 96:74-89.
9. Senn H.J., Jungi W.F., Amgwerd R., et al. Adjuvant chemoimmunotherapy with LMF+BCG in node-negative and node-positive breast cancer: 8 year results. Recent Results Cancer Res 1984, 96:90-101.
10. Ang P.T., Buzdar A.U., Smith T.L., Kau S., Hortobagyi G.N. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 1989, 7:1677-1684.
11. Pronzato P., Campora E., Amoroso D., et al. Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 1989, 12:481-485.
12. Ahmann D.L., O'Fallon J.R., Scanlon P.W., et al. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol 1982, 5:371-381.
13. Glucksberg H., Rivkin S.E., Rasmussen S., et al. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer 1982, 50:423-434.
14. Redmond C., Fisher B., Wieand H.S. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 1983, 67:519-526.
15. Mouridsen H.T., Rose C., Brincker H., et al. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Recent Results Cancer Res 1984, 96:117-128.
16. Epelbaum R., Haim N., Ben-Shahar M., Ron Y., Cohen Y. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1988, 24:533-538.
17. Kwak L.W., Halpern J., Olshen R.A., Horning S.J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990, 8:963-977.
18. Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170.
19. Trillet-Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A:319-324.
20. Pettengell R., Gurney H., Radford J.A., et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992, 80:1430-1436.
21. Glogowska I., Pienkowski T., Lemanska I., Sienkiewicz R., Kielanowska J. Dose intensity of adjuvant CMF chemotherapy program for breast cancer. Nowotwory 2001, 51:27-33.
22. Campbell C., Sawka C., Franssen E., Berinstein N.L. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support. Leuk Lymphoma 1999, 35:119-127.
23. Jackisch C., Jaber M., Burkamp U., et al. Maintenance of dose intensity in adjuvant chemotherapy of breast cancer in patients treated outside a clinical trial: results of a retrospective study. Geburtshilfe Frauenheilkd 2003, 63:333-341.
24. Faustino C, Afonso N, Sousa B, Espírito Santo J, Rodrigues H. Relative dose intensity reduction in breast cancer adjuvant chemotherapy. Poster presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (Abstract #4111), 2008.
25. Ferreira Filho AF, Di LA, Paesmans M, et al. The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. Ann Oncol 2002; 13:416-21.
26. Cardoso F., Ferreira Filho A.F., Crown J., et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study. Anticancer Res 2001, 21:789-795.
27. Leonard R.C.F., Miles D., Thomas R., Nussey F. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003, 89:2062-2068.
28. Yip D., Rangan A.M., Hamett P.R., Ahem V., Boyages J. Adjuvant chemotherapy for node-positive breast cancer: a retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil. The Breast 1999, 8:28-34.
29. Osby E., Hagberg H., Kvaloy S., et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003, 101:3840-3848.
30. Pettengell R., Schwenkglenks M., Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008, 87:429-430.
31. Terada Y., Nakamae H., Moriguchi R., et al. The impact of relative dose intensity of rituximab-CHOP on survival in diffuse large B-cell lymphoma patients. Blood 2008, 112(Suppl). Abstract #4931.
32. Morrison V.A., Picozzi V., Scott S., et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001, 2:47-56.
33. Clahsen P.C., Van De Velde C.J.H., Welvaart K., Repelaer Van Driel O.J., Sylvester R.J. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. J Clin Oncol 1995, 13:33-41.
34. Poikonen P., Saarto T., Lundin J., Joensuu H., Blomqvist C. Leukocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999, 80:1763-1766.
35. Ottevanger P.B., Verhagen C.A., Beex L.V. Quality of adjuvant chemotherapy in primary breast cancer in a non-trial setting. A comprehensive cancer centre study. The Breast Cancer Group of the Dutch Comprehensive Cancer Centre East (IKO). Eur J Cancer 1999, 35:386-391.
36. Mayers C., Panzarella T., Tannock I.F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001, 91:2246-2257.
37. Colleoni M., Price K., Castiglione-Gertsch M., et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 1998, 34:1693-1700.
38. Ottevanger P.B., De Mulder P.H., Grol R.P., Van L.H., Beex L.V. Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice. Anticancer Res 2002, 22:459-465.
39. Amadori D., Nanni O., Volpi A., et al. Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. Breast Cancer Res Treat 2008, 108:259-264.
40. Amador M.L., Jimeno A., Hitt R., Cortes-Funes H., Colomer R. Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer: a retrospective analysis. Am J Clin Oncol 2004, 27:269-273.
41. Saarto T., Blomqvist C., Rissanen P., Auvinen A., Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997, 75:301-305.
42. Chirivella I., Bermejo B., Insa A., et al. Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol 2006, 18(Suppl). Abstract #668.
43. Chirivella I., Bermejo B., Insa A., et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009, 114:479-484.
44. Hopkins S., Nicholas G., Verma S., Dent S., Gertler S. Relative dose intensity of FEC100: an analysis of outcomes. J Clin Oncol 2005, 23(Suppl):773. (Abstract).
45. Budman D.R., Berry D.A., Cirrincione C.T., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998, 90:1205-1211.
46. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19:602-11.
47. Earl H.M., Hiller L., Dunn J.A., et al. NEAT: National Epirubicin Adjuvant Trial: toxicity, delivered dose intensity and quality of life. Br J Cancer 2008, 99:1226-1231.
48. Lee K.W., Kim D.Y., Yun T., et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003, 98:2651-2656.
49. Bosly A., Bron D., Hoof A., et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008, 87:277-283.
50. Terada Y., Nakamae H., Nakane T., et al. The impact of relative dose intensity (RDI) of CHOP on outcome of diffuse large B-cell lymphoma: results of a single center study. Blood 2007, 110(11 Part 2). Abstract 4456.
51. Hirakawa T., Yamaguchi H., Gomi S., Yokose N., Inokuchi K., Dan K. Importance of relative dose intensity for survival in diffuse large B-cell lymphoma patients treated with CHOP-like regimen. Blood 2008, 112(Suppl). Abstract 3605.
52. Romieu G., Clemens M., Mahlberg R., et al. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol 2007, 64:64-72.
53. Lyman G.H., Dale D.C., Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003, 21:4524-4531.
54. Lyman G.H., Dale D.C., Friedberg J., Crawford J., Fisher R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004, 22:4302-4311.
55. Cameron D.A., Massie C., Kerr G., Leonard R.C.F. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003, 89:1837-1842.
56. De Graaf H., Willemse P.H.B., Bong S.B., et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 1996, 53:289-294.
57. Schaapveld M., de Vries E.G.E., Van der Graaf W.T.A., Otter R., Willemse P.H.B. Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. J Cancer Res Clin Oncol 2004, 130:581-590.
58. Trudeau M., Charbonneau F., Gelmon K., et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005, 6:886-898.
59. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
60. Pfreundschuh M., Schubert J., Ziepert M., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
61. Bang S.M., Heo D.S., Lee K.H., et al. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma: Results of a randomized controlled trial. Cancer 2000, 89:2521-2526.
62. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
63. Farquhar C., Marjoribanks J., Basser R., Hetrick S., Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 2005, CD003142.
64. Farquhar C.M., Marjoribanks J., Lethaby A., Basser R. High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 2007, 33:325-337.
65. Lyman G.H. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009, 7:99-108.
66. Hryniuk W., Frei E., Wright F.A. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 1998, 16:3137-3147.
67. Hryniuk W.M. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987, 14:65-74.
68. Hryniuk W.M., Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990, 8:1935-1937.
69. Longo D.L., Duffey P.L., DeVita V.T., Wesley M.N., Hubbard S.M., Young R.C. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991, 9:2042-2051.
70. Norton L., Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977, 61:1307-1317.
71. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997, 24(Suppl 10):S10.
72. Shayne M., Crawford J., Dale D.C., Culakova E., Lyman G.H. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006, 100:255-262.
73. Ribas A., Albanell J., Bellmunt J., et al. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 1996, 14:1573-1580.
74. Fridrik M.A., Greil R., Hausmaninger H., et al. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Worki ng Group for Medical Tumor Therapy. Ann Hematol 1997, 75:135-140.
75. Doorduijn J.K., van der Holt B., van Imhoff G.W., et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:3041-3050.
76. Pettengell R., Schwenkglenks M., Leonard R., et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008, 16:1299-1309.
77. Zinzani P.L., Pavone E., Storti S., et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997, 89:3974-3979.
78. Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007, 25:3158-3167.
79. Roché H., Fumoleau P., Spielmann M., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24:5664-5671.
80. Morrow T., Siegel M., Boone S., Lawless G., Carter W. Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer. Am J Med Qual 2002, 17:218-224.
81. Poole C.J., Earl H.M., Hiller L., et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006, 355:1851-1862.
82. Montemurro F., Gatti M., Redana S., et al. Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer. J Chemother 2006, 18:90-97.
83. Schwenkglenks M., Jackisch C., Constenla M., et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006, 14:901-909.
84. Shayne M., Culakova E., Poniewierski M.S., et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007, 110:1611-1620.
85. Raza M.S., Younus J., Welch S. Delivered relative dose intensity and febrile neutropenia rate with common adjuvant chemotherapy regimens: a review. J Clin Oncol 2008, 26(Suppl). Abstract 11505.
86. Picozzi V.J., Pohlman B.L., Morrison V.A., et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 2001, 15:1296-1306.
87. Case D.C., Desch C.E., Kalman L.A., et al. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma 2007, 7:354-360.
88. Kahlert S, Rosenfeld J, Mair K, Sorokina Y, Engel J, Friese K. Adjuvant chemotherapy for breast cancer prognostic impact of relative dose-intensity. Poster presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (Abstract 2075), 2008.
89. Papaldo P., Lopez M., Marolla P., et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005, 23:6908-6918.
90. Papaldo P., Ferretti G., Di Cosimo S., et al. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?. J Clin Oncol 2006, 24:3048-3055.
91. Gisselbrecht C., Haioun C., Lepage E., et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997, 25:289-300.
92. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA, eds. Philadelphia, PA: Lippincott, 1988:121-41.